EGFR and neoplasm: AREG, one of the seven ligands that bind and activate EGFR, can promote the differentiation of T cells into Tregs in the tumor microenvironment, and targeting AREG in the tumor microenvironment may inhibit tumor invasion and immunosuppression (Coniglio and Segall, 2021).